Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT ON (Rescuing Activity Of Na-channels) Study in Brugada Syndrome
2010-020117-87Phase 2Terminated
- Sponsor
- Fondazione Salvatore Maugeri
- Start
- May 2010
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gentamicin in Brugada syndrome, sponsored by Fondazione Salvatore Maugeri. Primary endpoint: Regression of Brugada ECG manifestations (ST segment elevation). Started May 2010; status: terminated.
02
Drugs
gentamicin
03
Conditions
Brugada syndrome
Beyond the preview
Go deeper on 2010-020117-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020117-87.